Vinflunine

Drug Profile

Vinflunine

Alternative Names: F-12158; Javlor; L-0070; Vinflunine ditartrate

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bladder cancer
  • Preregistration Breast cancer
  • Phase III Head and neck cancer; Urogenital cancer
  • No development reported Mesothelioma; Non-small cell lung cancer; Solid tumours
  • Discontinued Gastric cancer; Ovarian cancer

Most Recent Events

  • 01 Jul 2017 Pierre Fabre completes a phase III trial in Breast cancer (Combination therapy, Locally recurrent, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Taiwan, China, Singapore (IV) (NCT01953003)
  • 25 Jul 2016 Vinflunine licensed to Grupo Biotoscana in Colombia, Chile, Ecuador and Peru
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top